---
title: "688180.SH (688180.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688180.SH/news.md"
symbol: "688180.SH"
name: "688180.SH"
parent: "https://longbridge.com/en/quote/688180.SH.md"
datetime: "2026-05-21T01:57:02.285Z"
locales:
  - [en](https://longbridge.com/en/quote/688180.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688180.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688180.SH/news.md)
---

# 688180.SH (688180.SH) — Related News

### [Junshi Biosciences: JS207 has entered the Phase II clinical research stage](https://longbridge.com/en/news/286875089.md)
*2026-05-19T07:49:13.000Z*
> Junshi Biosciences stated at the earnings briefing that JS207 (PD-1/VEGF dual antibody) has entered the Phase II clinica

### [Healthcare Investment and Financing Daily (May 18): Biling Biotechnology completes RMB 400 million Series C financing](https://longbridge.com/en/news/286826996.md)
*2026-05-18T23:02:18.000Z*
> On May 18, 2026, a total of 6 financing events were disclosed in the healthcare sector, with a total financing amount of

### [In less than six months, two rounds of financing totaling over 600 million have been completed, and Biling Bio has secured 400 million in Series C financing](https://longbridge.com/en/news/286730401.md)
*2026-05-18T07:27:20.000Z*
> Biling Biotechnology recently completed a C round financing of 400 million yuan, exclusively invested by Junshi Venture 

### [In the first quarterly report, three dark horses emerged in innovative drugs](https://longbridge.com/en/news/286335048.md)
*2026-05-14T00:31:47.000Z*
> The financial performance of innovative pharmaceutical companies in 2026 has become the focus of investors. Hengrui Phar

### [](https://longbridge.com/en/news/285866520.md)
*2026-05-11T01:49:45.000Z*
> The concept of virus prevention and control is repeatedly active, with Hybribio Biotech rising over 13%. DAJY, SSSW, Hua

### [Hong Kong Biotech Stocks Decline Amid Market Volatility](https://longbridge.com/en/news/285017262.md)
*2026-05-04T02:00:29.000Z*
> Hong Kong's biotechnology sector is facing a downturn, with notable declines in key stocks. Akeso Inc.dropped over 9%, R

### [](https://longbridge.com/en/news/285017040.md)
*2026-05-04T02:00:16.000Z*
> Hong Kong biotechnology stocks fluctuated lower, with AKESO down over 9%, RemeGen down over 4%, and Junshi Biosciences d

### [智通港股通占比异动统计 |5 月 1 日](https://longbridge.com/en/news/284853789.md)
*2026-05-01T00:37:02.000Z*
> 根据 2026 年 4 月 30 日的数据，剑桥科技（06166）、恆生中国企业（02828）、盈富基金（02800）在港股通中的持股占比分别增加 13.28%、7.79% 和 2.98%。相对而言，国民技术（02701）、君实生物（018

### [Chinese innovative drugs can start looking at performance now](https://longbridge.com/en/news/284767233.md)
*2026-04-30T12:06:12.000Z*
> The Chinese innovative drug market is undergoing significant changes, with three biopharmaceutical companies, JUNSHI BIO

### [](https://longbridge.com/en/news/284473354.md)
*2026-04-29T01:23:00.000Z*
> Hong Kong stock biotechnology and pharmaceutical stocks have been strong for several consecutive days, with JUNSHI BIO a